Jaclyn Drass
Payments from drug & device makers
Across 502 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$1K
- AbbVie$1K
- AstraZeneca$818
- Abbott$769
- Boehringer Ingelheim$680
- Novo Nordisk$634
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 43 | $1,196 |
| AbbVie | 82 | $1,047 |
| AstraZeneca | 41 | $818 |
| Abbott | 38 | $769 |
| Boehringer Ingelheim | 31 | $680 |
| Novo Nordisk | 37 | $634 |
| Lilly USA, LLC | 27 | $463 |
| Otsuka America Pharmaceutical, Inc. | 22 | $424 |
| Lundbeck LLC | 24 | $411 |
| GSK | 24 | $406 |
| Pfizer | 18 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $198 |
| Idorsia Pharmaceuticals US Inc | 11 | $197 |
| Scilex Pharmaceuticals Inc. | 9 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $159 |
| Astellas Pharma US Inc | 6 | $156 |
| Bayer | 9 | $146 |
| Amgen | 9 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $129 |
| Azurity Pharmaceuticals, Inc. | 6 | $107 |
| Eisai Inc. | 4 | $87 |
| Mylan Specialty L.p. | 4 | $85 |
| Exact Sciences | 4 | $67 |
| Antares Pharma, Inc. | 3 | $50 |
| Almatica Pharma LLC | 3 | $50 |
| Currax Pharmaceuticals LLC | 3 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Inari Medical, Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$295
- REXULTI$121
- JARDIANCE$112
- Wegovy$111
- ZAVZPRET$106
How this compares
$9,341 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $25,646 |
| MounjaroTirzepatide | 18 | $21,033 |
| OzempicSemaglutide | 14 | $13,641 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $10,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,586 |
| FarxigaDapagliflozin Propanediol | 12 | $6,718 |
| EdarbiAzilsartan Medoxomil | 11 | $2,570 |
| Atorvastatin Calcium | 59 | $813 |
| Bupropion XlBupropion Hcl | 15 | $623 |
| Gabapentin | 45 | $616 |
| Pantoprazole Sodium | 26 | $453 |
| Metformin Hcl ErMetformin Hcl | 22 | $453 |
| Fluconazole | 22 | $433 |
| Duloxetine Hcl | 20 | $432 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 32 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $680 | $25,64642 claims |
| Lilly USA, LLCMounjaro | $463 | $21,03318 claims |
| Novo NordiskOzempic | $634 | $13,64114 claims |
| GSKTrelegy Ellipta | $406 | $9,58614 claims |
| AstraZenecaFarxiga | $818 | $6,71812 claims |
| Almatica Pharma LLCSertraline Hcl | $50 | $10920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Jillian OakleafTulsa$15K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Teresa DonnellTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.